Amarin EVAPORATE Study Results

When will the EVAPORATE study results be published?


A third study will evaluate the reduction of coronary plaque using Vascepa® (icosapent ethyl). This study, titled EVAPORATE ("Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients with Elevated Triglycerides [200-499 mg/dL] on Statin Therapy"), will be led by Matthew J. Budoff, M.D., Professor, David Geffen School of Medicine at UCLA and program director of Cardiac CT at Harbor-UCLA Medical Center.

EVAPORATE will be the first study to use MDCT to evaluate the effects of icosapent ethyl on plaque characteristics in patients with persistent high triglyceride (TG) levels. MDCT, multidetector computed tomography, is an advanced technology for diagnostic imaging. The EVAPORATE study will be presented as a poster (abstract #143).

Post A Reply

Report this entire thread

The reason we ask for your email address is to ensure the reporting feature is not abused. Once you report a thread a confirmation email will be sent to you requiring that you did in fact mean to do this action. This also gives us a way to get in touch with you privately to discuss your reasoning if we feel the thread has been reported without merit.

Your email address will never be used for any other reason and will never be sold to email marketers.

A reason is required.

Full slide deck presented at AHA.

Final results of EVAPORATE anticipated in early 2020.

post

Full slide deck presented at AHA.

post

This should help put the data into perspective. Vascepa will be looked at as an essential part of the process in preventing heart disease for those at risk. Not a bad thing at all.

Will these results help or hurt Vascepa from a labeling perspective with the FDA, which is due by December 28th?

post

This should help put the data into perspective. Vascepa will be looked at as an essential part of the process in preventing heart disease for those at risk. Not a bad thing at all.

post

Liquid stent sounds good.

5 Billion more in sales after positive EVAPORATE data sounds even better!

post

I would love to get more context from those images but if that is an actual image from EVAPORATE that changes this entire game. Imagine Vascepa being a medicinal "liquid stent" - The science for Vascepa gets better every single day and those tired short arguments go out the window.

Liquid stent sounds good.

post

EVAPORATE plus this new study showing stents and bypass aren't any better than medical management are what changes the entire narrative of the Vascepa story.

Use this link, the WSJ story has a paywall.

post

I would love to get more context from those images but if that is an actual image from EVAPORATE that changes this entire game. Imagine Vascepa being a medicinal "liquid stent" - The science for Vascepa gets better every single day and those tired short arguments go out the window.

EVAPORATE plus this new study showing stents and bypass aren't any better than medical management are what changes the entire narrative of the Vascepa story.

post

I would love to get more context from those images but if that is an actual image from EVAPORATE that changes this entire game. Imagine Vascepa being a medicinal "liquid stent" - The science for Vascepa gets better every single day and those tired short arguments go out the window.

post

Here is an image from EVAPORATE that was posted during the AdCom yesterday. Study is presented this upcoming Monday.

post

Will the results of EVAPORATE be included at AdCom or does the embargo take precedence?

Here is an image from EVAPORATE that was posted during the AdCom yesterday. Study is presented this upcoming Monday.

post

Loading...


Load More

Report this post

The reason we ask for your email address is to ensure the reporting feature is not abused. Once you report a post a confirmation email will be sent to you requiring that you did in fact mean to do this action. This also gives us a way to get in touch with you privately to discuss your reasoning if we feel the post has been reported without merit.

Your email address will never be used for any other reason and will never be sold to email marketers.

A reason is required.